SEC EDGARAUG 191 min read$INSM

SHAROKY MELVIN MD sold $638K of INSM (indirect holdings)

SHAROKY MELVIN MD sold 5,000 indirectly-held shares of INSMED Inc (INSM) at $127.53 ($0.64M total) on 2026-08-17.

Original reporting

SEC EDGAR · SHAROKY MELVIN MD

Published Aug 19, 2026, 8:10 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 19, 2026, 8:16 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$INSM

Neutral

medium confidence

Mentioned

$INSM

Relevance

5/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$INSMNeutralLow

Why it matters

While the transaction is new, its modest size limits market impact.

Market read

The filing is a primary source but offers limited trading relevance due to its small scale.

What to watch

Potential upcoming financing needs or personal tax considerations for the director.

Relevance 5/10Novelty 6/10Timing: today

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$INSMNeutralMedium confidence

Context

Director Sharoky Melvin sold 5,000 shares for $637,650, reducing holdings to zero.

Expected impact

Potential slight downward pressure on INSM price.

Evidence & confidence

Sale size is under $1M and represents a complete exit by a director; market may view it as a minor negative cue.

Market effects

Sector

Minimal impact on the broader medical device sector.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity in micro‑caps.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

Company
INSMED Inc
Issuer of the insider transaction.
Individual
Sharoky Melvin MD
Director of INSMED Inc who sold shares.

Read at source ← All news

SEP 2

$INSMHighAI 8/10

Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business

Insmed (INSM) reported Q2 2026 revenue of $425.5M, up 296% YoY, with net loss narrowing to $13.2M. BRINSUPRI sales reached $309.2M, up 49% QoQ. The company raised full-year BRINSUPRI guidance to $1.25B-$1.40B. Insmed also increased its peak revenue estimate for lead programs to over $14B. Expenses rose due to commercial buildout and R&D spending.

insidermonkey.com2 min

SEP 1

$INSMMedAI 8/10

Is Insmed (INSM) Undervalued Following Japan Approval For BRINSUPRI?

Insmed (INSM) received approval for BRINSUPRI in Japan, adding to U.S. and European clearances. Shares rose 2.78% to $121.84, with a 30-day return of 23.57% but a YTD decline of 31.21%. Analysts suggest a fair value of $197.14, indicating potential undervaluation, but risks include approval delays and reimbursement challenges.

simplywall.st3 min

AUG 28

$GILDMedAI 8/10

Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

finanznachrichten.de3 min

AUG 24

$INSMHighAI 8/10

Mizuho raises Insmed stock price target to $195 on Japan approval

Mizuho raised its price target for Insmed (INSM) to $195, citing Japan's approval of Brinsupri. The stock trades at $123.98, with a market cap of $27.1B. Insmed reported strong Q2 2026 revenue, raising guidance for Brinsupri and TPIP. Analysts maintain a strong buy rating, with upward earnings revisions.

investing.com2 min

AUG 24

$INSMHighAI 9/10

BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Insmed Inc. (INSM) announced Japan's approval of BRINSUPRI® (brensocatib) for treating non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12+. The approval is based on Phase 3 ASPEN study results showing reduced pulmonary exacerbations and lower lung function decline. BRINSUPRI is now approved in the U.S., Europe, and Japan.

prnewswire.com2 min

AUG 19

$INSMMed

How Insmed’s Sharply Narrowed Q2 2026 Net Loss At Insmed (INSM) Has Changed Its Investment Story

Insmed Inc. (INSM) reported a sharply narrowed net loss of $13.24M in Q2 2026, down from $321.69M a year earlier, with loss per share at $0.06 vs. $1.70. The company's H1 2026 net loss also improved to $176.81M from $578.27M, indicating lower cash burn. Insmed's investment narrative focuses on its respiratory portfolio, particularly brensocatib, with guidance projecting $1B in 2026 BRINSUPRI revenue and $450M-$470M from ARIKAYCE. The company aims for $4.1B revenue and $1B earnings by 2029, requi

simplywall.st2 min